Haematopoietic stem cell transplantation in MS
|
|
- Dina Lucas
- 8 years ago
- Views:
Transcription
1 jan fagius, neurologkliniken Haematopoietic ti stem cell transplantation in MS Living with MS: Today and tomorrow, Göteborg Oct 12, 2010 Jan Fagius, Dept of Neurology Akademiska sjukhuset / University Hospital Uppsala, Sweden
2 jan fagius, neurologkliniken Haematopoietic stem cell transplantation, HSCT Leukaemia patients with autoimmun disease treated dby HSCT show long time remission of AID. EAE (animal model of MS) strongly improved dby HSCT Uppgrading g of the immune system - but what happens?: repair of immunological imbalance total (?) () elimination of autoreactive lymfocytes y In theory a way to cure MS?!? (Hintzen, Mult Scler 8:155, 2002) If so, must be performed before parts of CNS are irreversibly damaged, i.e. early treatment emphasized as always in MS
3 The importance of early treatment
4 HSCT in autoimmune disease Animal studies allogeneic (syngeneic), since around 1980 autologous since around 1990 EAE early 90s (Burt et al 1995) Patient treatments allogeneic for AID - too dangerous! autologous first attempt jan fagius, neurologkliniken 1996 European Blood and Marrow Transplant (EBMT) Working Party for Autoimmune Disorders
5 1. Mobilisation Cyclophosphamide and G-CSF; bone marrow cells exit to circulation 2. Cell harvest after 10 days leukapheresis HCST, procedure 3. Conditioning therapy kill the immune system myelo- / immunoablation cytotoxic treatment (chemotherapy, radiation, antibodies) 4. Reinfusion of stem cells / (purging) one week later. Anti-thymocyte globulin, ATG The stem cells start to produce The stem cells start to produce a new, purified immune system
6 jan fagius, neurologkliniken Our first patient t Woman aged 31, healthy. Sept 2003 facial palsy; recovered Dec weakness one leg, marked fatigue, recovered January 2004 unsteady gait Januari bilateral optic neuritis. MRI MS February subtotal paraparesis, urinary bladder paresis Steroids, vision och leg function improved, able to go March right hemiparis, total paraparesis. Steroids 0 effect Two weeks later tetraparesis; EDSS 9,0 Intense plasmapheresis, arms improved To our hospital April 2004, EDSS 8,0
7 E D S S 6 5 S Patient no 1, woamn 32 år, HSCT MAY2004 IB Months before and after HSCT
8 jan fagius, neurologkliniken HSCT Procedure Dept of Haematology, Uppsala: (Ova / sperm saving; heart & thyroid function) Mobilisation Cyclophosphamide + G-CSF (Neupogen) Harvest 10 days Conditioning, myeloablation y BEAM BCNU, etoposide, cytosine-arabinoside, melphalan) Reinfusion day 6-7 ATG, antithymocyte globulin
9 15 pts (10 women) having undergone HSCT; Sept -10 ~10 relapses/8 mo 0 relapse/77 mo 8 relapses /10 mo 0 relapse/71 mo 14 relapses /11 mo 0 relapse/65 mo 7 relapses /6 mo 0 relapse/64 mo 10 relapses /10 mo 1 relapse/59 mo 6 relapses /7 mo 0 relapse/56 mo 6 severe relapses /4 mo 0 relapse/71 mo Totally 99 relapses/158 patient mo 3 relapses/695 patient mo patients on EDSS 6,0-7,0; too late 8 patients on EDSS 0-2,5, ADL healthy 3 patients on EDSS 3,0-3,5 ADL slight disturbance IB EE EJ SP E D S S JL MP ASU EH DG TF LÅ MC TM SA 0 MA Time, months
10 HSCT for MS Outcome 8 previous series; median follow-up mo 215 pats RRMS 32 SPMS 145 PPMS improved Serie1 % 50 Serie2 40 worse Serie Fassas 1 Nash 2 Burt 3 Saiz 4 Sacc 5 Samijn 6 7Ni Su 8 Uppsala 9 n unchanged
11 HSCT for MS Outcome 8 previous series; median follow-up mo 215 pat RRMS 32 SPMS 145 PPMS 38 Δ ED DSS Serie1 best 2 Serie2 di 1? Fassas Nash Burt Saiz Sacc Samijn Ni Su Uppsala n median worst Serie3
12 jan fagius, neurologkliniken Review Burt et al, Arch Neurol 2005; 62:860-4 Review of international experiences so far by HSCT for MS. (Choice of myeloablative or lymfo/immunoablative treatment was discussed - se below) Little success with progressive avanced MS Conclusion - if treatment is taken into account, it should be in the inflammatory phase of MS, before irreversible degenerative changes are present
13 Degeneration continues after HSCT. Metz et al. Brain 2007; 130: HSCT cases, 5 fatalities 20 days 1,5 years after HSCT. Histopatology of the brain. Totally 53 active and non-active lesions according to previously published criteriae were defined. No inflammatory cell infiltrates. Mk Makrophages 12 x more common in active lesions. Demyelinisation and axonal loss goes on, without inflammatory features.
14 HSCT for MS Why is the procedure effective? jan fagius, neurologkliniken The inflammatory tendency stopped/strongly inhibited Erroneously programmed lymfocytes eliminated (Almost) no further inflammatory attacks The CNS is given chance to manifest its recovery ability Recovery not due to the treatment, but given possibility to occur. How do we know that the immune system program error does not return with the reinfused stem cells with recurrent disaese activity later on? We do not know!
15 HSCT for MS Experiences after 15 Uppsala cases: jan fagius, neurologkliniken Fever/infections as expected (most patients) Sepsis 2 cases Relapse at mobilisation 1 case Serum sickness-like e reactions -from ATG?? 2 cases myalgia, shiering, fever (steroids added with ATG) Progressive visual loss 1 case Herpes zoster some months post-hsct 1 case 3 mild relapses 7, 18 and 32 months after HSCT No CMV or EBV reactivations so far 4 pregnancies, naturally occurring ; 2 deliveries
16 HSCT for MS Current indications in Uppsala (april 2010): Confirmed MS diagnosis Aggressive, malignant, disease, predominantly RRMS Short disease duration/ high activity duration Documented, recent ability for function recovery, ~ the last 3-6 months Low grade of irreversible lesions in CNS EDSS level?? > 5,5 at least during relapse MRI may contribute to the decision Dept of Neurology in collaboration with Dept of Haematology
17 HSCT for MS MRI findings may support treatment decision (MA, 35 yrs) T1, Gad > 50 Gadenhancing lesions 3 mo post- HSCT No Gad- enhancing lesion
18 HSCT for MS MRI findings may support treatment decision (MC, 25 yrs) T1, Gad > 50 Gadenhancing lesions 5 mo post- HSCT No Gad- enhancing lesion
19 jan fagius, neurologkliniken HSCT for MS Burt et al Lancet Neurol. Online January 30,2009 Lancet Neurol Mar;8(3):244-53
20 jan fagius, neurologkliniken HSCT och MS Burt et al Lancet Neurology 2009 Mobilization: i Cyclophosphamide 2g/m 2 body surface Filgrastim i (G-CSF; Neupogen) s.c. 10 μg/kg from day 5 Conditioning: Cyclophosphamide 200 mg/kg, divided on 4 days (-5-2) [day 0 = reinfusion] (Alemtuzumab 17 pts) ; ATG (4 pts) From day 5 filgrastim s.c., 5 μg/kg/day until neutrophil recovery Rather heavy profylactic antibiotic treatment t t after HSCT
21 HSCT och MS Burt et al Lancet Neurology 2009 jan fagius, neurologkliniken IFN-treated t RRMS patients, t yrs, treatment failure two steroid idtreated t relapses last t12 mo, or one steroid treated relapse +1MRIGd MRI-Gd-lesion on another occasion; last t12 mo (purely sensory relapses not incl criterium) > 3 months since last relapse EDSS 2,0-5,5; Pi Primary outcome measures: at t3 years progression-free survival and improvement of ffunction
22 jan fagius, neurologkliniken HSCT och MS Burt et al Lancet Neurology 2009 IFN-treated 21 pats (11 f) , median age 33 (20-53) EDSS level 3,1 (2,0-5,5); MS-dur 5 yrs (1,5-10) Follow-up median 37 (24-48) months 5 pats relapse 0 progress of dysfunction Total disease-activity-free survival 13 pat (62%) 17/21 pats improved 1EDSSstep Sign effects: EDSS, Scripps NRS, PASAT, 25-foot walk, SF-36
23 jan fagius, neurologkliniken HSCT och MS Burt et al Lancet Neurology 2009 An immuno-ablative regimen, not myelo-ablative! g, y Less dangerous. Fewer acute complications. Weaker effect??
24 HSCT och MS Burt et al Lancet Neurology /21 pats improved EDSS 1 steps. Details: 7 pats 1-1,5 steps 6 pat 2-2,5 steps median value 4pats 3steps 2 pats 0,5 step 2 pats no change 0 pat deteriorated The Uppsala experience 13/15 pats improved EDSS 1 steps. Details: 4 pats 1-1,5 steps 2 pats 3,5 steps 4 pats 4 steps median value 2 pats 6,5-7 steps 1 pat deterioration 0,5 step jan fagius, neurologkliniken
25 HSCT och MS Burt et al Lancet Neurology 2009 Blood count recovery 13/21 pats needed derytrocyte transfusion 15/21 pats needed platelet transfusion (< trc) Infections / complications i 5 pats neutropenic fever without signs of infection or detected patogen (NB prophylactic ab-treatment) No bacterical growth in any ypatient! jan fagius, neurologkliniken Discharge from hematologal oga ward median day 11 (8-13) Markedly fewer complications than our experience Somewhat less good results s than ours
26 HSCT for MS Probably the most effective treatment for MS might be a way to cure MS ; statement requiring a life-long follow-up High cost-effectiveness - one single procedure But formally not documented effect i.e. no controlled study performed ASTIMS - HSCT vs mitoxantron - still alive? MIST - slowly advancing, -neurologists hesitating, i the average neurologist is not brave! jan fagius, neurologkliniken
27 ASTIMS BEAM + ATG is investigative e treatment. BCNU Etoposid cytosin Arabinoside Melphalan Mitoxantrone 20 mg + Methylprednisolone 1g each month for 6 months.
28 HSCT for MS Burt et al Lancet Neurology 2009 jan fagius, neurologkliniken MIST-study: To assess the efficacy of autologous PBSCT versus FDA approved standard of care for inflammatory multiple sclerosis failing interferon therapy. Immuno-ablative regimen (= cyclophosphamide) vs /mainly/ natalizumab Primary Endpoint: Disease progression, 1 point EDSS at least 6 months apart Patients will be followed for 5 years after randomization. Secondary Endpoints: Number of relapses A number of detailed functions Ambulation index Twenty-five foot timed walk Nine hole PEG test PASAT SF-36 and MSQOL Scripps NRS Survival MRI enhancing lesions and T1 and T2 burden of disease
29 HSCT for MS Strong need for a controlled study immuno-ablative i HSCT cyclophosphamide/atg regimen vs best available routine treatment natalizumab inclusion i criteriae i corresponding to today s treatment indications for natalizumab jan fagius, neurologkliniken C h d b li d? Can such a study be realized? It must be!!
30 Thank you
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
More informationWhat did we learn from ASTIMS?
What did we learn from ASTIMS? Riccardo Saccardi, Florence Gianluigi Mancardi, Genova On behalf of the EBMT-ADWP Multiple Sclerosis - Background Affects CNS in young adults (20-40 years) Socioeconomically
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationSupplementary Online Content
Supplementary Online Content Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting
More informationManaging Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre
Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability
More informationFor a full list of MS Trust publications, to sign up for Open Door and much more visit our website at www.mstrust.org.uk
Stem cell therapy We hope you find the information in this factsheet helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information team and they will help find
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationHealth Policy Advisory Committee on Technology New and Emerging Health Technology Report
Health Policy Advisory Committee on Technology New and Emerging Health Technology Report Stem cell therapy for non-haematological (autoimmune) indications March 2015 State of Queensland (Queensland Department
More informationAdvanced Multiple Sclerosis: Progressive MS Epidemiology
Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationUsing the MS Clinical Course Descriptions in Clinical Practice
Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationNews on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS
News on modifying diseases therapies Michel CLANET CHU Toulouse France ECTRIMS Current treatment strategies Future oral treatments Future non oral treatments Drug safety and risks CIS at risk of MS Active
More informationAbout MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?
An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationTreatment Optimization in MS: When to Start, When to Shift, when to Stop
Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationMultiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationHow To Use A Drug In Multiple Sclerosis
Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationTreatment guidelines for relapsing MS and the two step approach for disease modifying therapy
Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be
More informationUnderstanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More information- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -
PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with
More informationTherapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation. Marianne E. McPherson Yee, MD, MSc
Therapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation Marianne E. McPherson Yee, MD, MSc Sickle Cell Treatment Options Supportive Care Newborn Screen PCN Immunizations Education
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationPatient Sticker Multiple Sclerosis Ambulatory Emergency Care Pathway
Multiple Sclerosis Ambulatory Emergency Care Pathway 1 Consultant: Dr M Oldfield Consultant: Dr D Harris Lead Nurse: Catie Paterson Ambulatory Emergency Care (AEC) Unit Patient From ED (Emergency Department)
More informationMultiple Sclerosis: An imaging review and update on new treatments.
Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter
More informationThe Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationBone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer
Bone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer A Review of the Research for Parents and Caregivers Is This Information Right
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationChapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.
Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationAutologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
TRANSPLANTATION Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life Riccardo Saccardi, Gian Luigi Mancardi, Alessandra Solari,
More informationAutologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis
Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis Nikolai Pfender 1, Riccardo Saccardi 2, Roland Martin 1 1 Neuroimmunology and MS Research, Department
More informationNatalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY
Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru381 Topic: Lemtrada TM, alemtuzumab Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationSTUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan
STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly
More informationAdult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationMultiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
More informationMultiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON
Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based
More informationSummary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationTITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines
TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationAutologous non-myeloablative hematopoietic stem cell transplantation for
Autologous non-myeloablative hematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis Richard K Burt MD 1, Yvonne Loh MD 1, Bruce Cohen MD 2, Dusan Stefosky MD 3, Roumen Balabanov
More informationß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate
ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationRelapsing remitting MS
An introduction to Relapsing remitting MS What does it mean when you are diagnosed with relapsing remitting MS? There are three main types of MS: relapsing remitting MS, primary progressive MS and secondary
More informationMS ECHO: Update on MS treatment. Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology 10 14 2015
MS ECHO: Update on MS treatment Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology 10 14 2015 Conflict of Interest Dr. Stobbe has no conflicts of interest to disclose
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationOptic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationAutologous Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
Review Article 421 Autologous Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis Yvonne SM Loh, 1 MBBS, MRCP, FAMS, William YK Hwang, 1 MBBS, MRCP, FAMS, Pavanni Ratnagopal,
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationOHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationLife with MS: Striving for Maximal Independence & Fulfillment
Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationMRI in Differential Diagnosis
MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards
More informationMEDICAL POLICY HIGH-DOSE CHEMOTHERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL RESCUE FOR AUTOIMMUNE DISEASES, INCLUDING MULTIPLE SCLEROSIS MP-9.
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): Effective Date: June 17, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the
More informationSummary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
More information